Histone H3K36me2 Demethylase KDM2A Promotes Bladder Cancer Progression Through Epigenetically Silencing RARRES3

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2022 Jun 13

PMID 35697678

Authors

Bing Lu

Jiatian Wei

Houhong Zhou

Jie Chen

Yuqing Li

Liefu Ye

Wei Zhao

Song Wu

Affiliations

Soon will be listed here.

Abstract

Epigenetic dysregulation contributes to bladder cancer tumorigenesis. H3K36me2 demethylase KDM2A functions as an important epigenetic regulator of cell fate in many types of tumors. However, its role in bladder cancer remains unknown. Here, we revealed a positive correlation between KDM2A gene copy number gain and upregulation of KDM2A mRNA expression in bladder cancer. Moreover, a super-enhancer (SE) driving KDM2A transcription was found in high-grade bladder cancer, resulting in a significantly higher expression of KDM2A mRNA compared to that in low-grade bladder tumors. KDM2A knockdown (KD) decreased the proliferation, invasion, and spheroid formation of high-grade bladder cancer cells and inhibited tumor growth in mouse xenograft models. Furthermore, we identified RARRES3 as a key KDM2A target gene. KDM2A suppresses RARRES3 expression via demethylation of H3K36me2 in the RARRES3 promoter. Intriguingly, RARRES3 KD attenuated the inhibitory effects of KDM2A depletion on the malignant phenotypes of high-grade bladder cancer cells. The combination of the KDM2A inhibitor IOX1 and the RARRES3 agonist all-trans retinoic acid (ATRA) synergistically inhibited the proliferation of high-grade bladder cancer cells, suggesting that the KDM2A/RARRES3 axis may be a promising therapeutic target for the treatment of high-grade bladder cancer.

Citing Articles

Current advances and future directions in targeting histone demethylases for cancer therapy.

Shin J, Yoo H, Roe J Mol Cells. 2025; 48(3):100192.

PMID: 39938867 PMC: 11889978. DOI: 10.1016/j.mocell.2025.100192.

Identification and Validation of T-Cell Exhaustion Signature for Predicting Prognosis and Immune Response in Pancreatic Cancer by Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data.

Zhu Y, Tan L, Luo D, Wang X Diagnostics (Basel). 2024; 14(6).

PMID: 38535087 PMC: 10968840. DOI: 10.3390/diagnostics14060667.

A gene signature linked to fibroblast differentiation for prognostic prediction of mesothelioma.

Liu J, Lu Y, Liu Y, Zhang W, Xian S, Wang S Cell Biosci. 2024; 14(1):33.

PMID: 38462627 PMC: 10926647. DOI: 10.1186/s13578-023-01180-7.

Inhibition of demethylase by IOX1 modulates chromatin accessibility to enhance NSCLC radiation sensitivity through attenuated PIF1.

Li Q, Qin K, Tian Y, Chen B, Zhao G, Xu S Cell Death Dis. 2023; 14(12):817.

PMID: 38086789 PMC: 10716120. DOI: 10.1038/s41419-023-06346-2.

The Role of KDM2A and H3K36me2 Demethylation in Modulating MAPK Signaling During Neurodevelopment.

Ren Z, Tang H, Zhang W, Guo M, Cui J, Wang H Neurosci Bull. 2023; 40(8):1076-1092.

PMID: 38060137 PMC: 11306490. DOI: 10.1007/s12264-023-01161-3.

References

Fang Y, Tang Y, Zhang Y, Pan Y, Jia J, Sun Z . The H3K36me2 methyltransferase NSD1 modulates H3K27ac at active enhancers to safeguard gene expression. Nucleic Acids Res. 2021; 49(11):6281-6295. PMC: 8216457. DOI: 10.1093/nar/gkab473. View

Lachner M, OSullivan R, Jenuwein T . An epigenetic road map for histone lysine methylation. J Cell Sci. 2003; 116(Pt 11):2117-24. DOI: 10.1242/jcs.00493. View

van Rhijn B, Burger M, Lotan Y, Solsona E, Stief C, Sylvester R . Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56(3):430-42. DOI: 10.1016/j.eururo.2009.06.028. View

Hnisz D, Abraham B, Lee T, Lau A, Saint-Andre V, Sigova A . Super-enhancers in the control of cell identity and disease. Cell. 2013; 155(4):934-47. PMC: 3841062. DOI: 10.1016/j.cell.2013.09.053. View

Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M . All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene. 2005; 24(33):5246-51. DOI: 10.1038/sj.onc.1208725. View

Zhu L, Li Q, Wong S, Huang M, Klein B, Shen J . ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. Cancer Discov. 2016; 6(7):770-83. PMC: 4930721. DOI: 10.1158/2159-8290.CD-16-0058. View

Wang Y, Zhu L, Guo M, Sun G, Zhou K, Pang W . Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2. Cell Death Discov. 2021; 7(1):19. PMC: 7815777. DOI: 10.1038/s41420-021-00402-6. View

Lin Q, Wu Z, Yue X, Yu X, Wang Z, Song X . ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation. EBioMedicine. 2020; 53:102676. PMC: 7047184. DOI: 10.1016/j.ebiom.2020.102676. View

Dubuc A, Remke M, Korshunov A, Northcott P, Zhan S, Mendez-Lago M . Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol. 2012; 125(3):373-84. PMC: 3580007. DOI: 10.1007/s00401-012-1070-9. View

10.

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

11.

Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V . Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017; 49(9):1408-1413. DOI: 10.1038/ng.3921. View

12.

Yuan S, Natesan R, Sanchez-Rivera F, Li J, Bhanu N, Yamazoe T . Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression. Cancer Discov. 2020; 10(6):854-871. PMC: 7269857. DOI: 10.1158/2159-8290.CD-19-1299. View

13.

Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A . Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene. 2011; 31(29):3431-43. DOI: 10.1038/onc.2011.506. View

14.

Wang L, Shilatifard A . UTX Mutations in Human Cancer. Cancer Cell. 2019; 35(2):168-176. PMC: 6589339. DOI: 10.1016/j.ccell.2019.01.001. View

15.

Soukup V, Capoun O, Cohen D, Hernandez V, Babjuk M, Burger M . Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines.... Eur Urol. 2017; 72(5):801-813. DOI: 10.1016/j.eururo.2017.04.015. View

16.

Du J, Ma Y, Ma P, Wang S, Fan Z . Demethylation of epiregulin gene by histone demethylase FBXL11 and BCL6 corepressor inhibits osteo/dentinogenic differentiation. Stem Cells. 2012; 31(1):126-36. DOI: 10.1002/stem.1255. View

17.

Wang Y, Sun B, Zhang Q, Dong H, Zhang J . p300 Acetylates JHDM1A to inhibit osteosarcoma carcinogenesis. Artif Cells Nanomed Biotechnol. 2019; 47(1):2891-2899. DOI: 10.1080/21691401.2019.1638790. View

18.

Margueron R, Trojer P, Reinberg D . The key to development: interpreting the histone code?. Curr Opin Genet Dev. 2005; 15(2):163-76. DOI: 10.1016/j.gde.2005.01.005. View

19.

Fnu S, Williamson E, De Haro L, Brenneman M, Wray J, Shaheen M . Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining. Proc Natl Acad Sci U S A. 2010; 108(2):540-5. PMC: 3021059. DOI: 10.1073/pnas.1013571108. View

20.

Kawakami E, Tokunaga A, Ozawa M, Sakamoto R, Yoshida N . The histone demethylase Fbxl11/Kdm2a plays an essential role in embryonic development by repressing cell-cycle regulators. Mech Dev. 2014; 135:31-42. DOI: 10.1016/j.mod.2014.10.001. View